You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOrphenadrine
Accession NumberDB01173  (APRD00097)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]
Structure
Thumb
Synonyms
2-(phenyl-o-tolylmethoxy)ethyldimethylamine
2-methyldiphenhydramine
beta-Dimethylaminoethyl 2-methylbenzhydryl ether
Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine
N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine
N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine
N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine
o-methyldiphenhydramine
o-monomethyldiphenhydramine
Orfenadrina
ORPHENADRINE
Orphenadrinum
Phenyl-O-tolylmethyl dimethyaminoethyl ether
β-dimethylaminoethyl 2-methylbenzhydryl ether
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disipal Tab 50mgTablet50 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1957-12-312002-07-09Canada
NorflexLiquid30 mgIntramuscular; IntravenousValeant Canada Lp Valeant Canada S.E.C.1961-12-312014-07-30Canada
Orphenadrine Citrate Injection, USPLiquid30 mgIntramuscular; IntravenousSterimax Inc1996-12-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Orphenadrine CitrateTablet, extended release100 mg/1Oralbryant ranch prepack1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralRx Change Co.2014-11-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralUnit Dose Services1998-06-19Not applicableUs
Orphenadrine CitrateInjection30 mg/mLIntramuscular; IntravenousWatson Laboratories, Inc.2010-07-08Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralA S Medication Solutions1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralPd Rx Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralPreferred Pharmaceuticals, Inc1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralRebel Distributors Corp1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralPreferred Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralClinical Solutions Wholesale1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralDispensing Solutions, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-02-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralA S Medication Solutions1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralH.J. Harkins Company, Inc.2000-06-23Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralBlenheim Pharmacal, Inc.2011-08-10Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralGAVIS Pharmaceuticals, LLC1998-06-19Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralProficient Rx LP2000-02-15Not applicableUs
Orphenadrine CitrateInjection, solution30 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2011-10-01Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralRed Pharm Drug, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralAmerican Health Packaging2014-09-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralAv Kare, Inc.2015-11-022016-03-18Us
Orphenadrine CitrateTablet, extended release100 mg/1OralNu Care Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralPhysicians Total Care, Inc.2000-04-17Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralSTAT Rx USA LLC2000-06-23Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralMedsource Pharmaceuticals2000-02-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralImpax Generics2000-06-23Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralAidarex Pharmaceuticals LLC1998-06-19Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralProficient Rx LP1998-06-19Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralCarilion Materials Management2000-02-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralSTAT Rx USA LLC2000-06-23Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralPreferred Pharmaceuticals, Inc.2000-02-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralPd Rx Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine CitrateInjection30 mg/mLIntramuscular; IntravenousAkorn, Inc.2006-10-17Not applicableUs
Orphenadrine CitrateTablet100 mg/1OralEon Labs, Inc.2000-02-15Not applicableUs
Orphenadrine CitrateTablet, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-02-07Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NorflexTablet, extended release100 mgOralValeant Canada Lp Valeant Canada S.E.C.1993-12-312014-07-30Canada
Orfenace Tablet 100mgTablet100 mgOralSterimax Inc1994-12-31Not applicableCanada
Sandoz OrphenadrineTablet, extended release100 mgOralSandoz Canada Incorporated2001-02-27Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
AntiflexNot Available
BanflexNot Available
BiorphenNot Available
DisipalNot Available
FlexojectNot Available
Mio-RelNot Available
MyolinNot Available
OrfenAceNot Available
OrfroNot Available
Brand mixtures
NameLabellerIngredients
Norgesic3 M Pharmaceuticals
Norgesic Forte3 M Pharmaceuticals
Norgesic Forte Tab3 M Pharmaceuticals, A Division Of 3 M Canada Company
Norgesic Tab3 M Pharmaceuticals, A Division Of 3 M Canada Company
Orphenadrine Citrate, Aspirin and CaffeineRebel Distributors Corp
Salts
Name/CASStructureProperties
Orphenadrine citrate
4682-36-4
Thumb
  • InChI Key: MMMNTDFSPSQXJP-UHFFFAOYNA-N
  • Monoisotopic Mass: 461.204966973
  • Average Mass: 461.5048
DBSALT000400
Orphenadrine hydrochloride
341-69-5
Thumb
  • InChI Key: UQZKYYIKWZOKKD-UHFFFAOYSA-N
  • Monoisotopic Mass: 305.1546421
  • Average Mass: 305.85
DBSALT001021
Categories
UNIIAL805O9OG9
CAS number83-98-7
WeightAverage: 269.3813
Monoisotopic: 269.177964363
Chemical FormulaC18H23NO
InChI KeyQVYRGXJJSLMXQH-UHFFFAOYSA-N
InChI
InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
IUPAC Name
dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
SMILES
CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C
Pharmacology
IndicationIndicated for the treatment of Parkinson's disease.
Structured Indications
PharmacodynamicsOrphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.
Mechanism of actionOrphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate receptor ionotropic, NMDA 2DProteinyes
antagonist
HumanO15399 details
Glutamate receptor ionotropic, NMDA 1Proteinyes
antagonist
HumanQ05586 details
Glutamate receptor ionotropic, NMDA 3BProteinyes
antagonist
HumanO60391 details
Glutamate receptor ionotropic, NMDA 3AProteinyes
antagonist
HumanQ8TCU5 details
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium channel protein type 10 subunit alphaProteinunknown
inhibitor
HumanQ9Y5Y9 details
Related Articles
AbsorptionOrphenadrine is almost completely absorbed in the gastrointestinal tract.
Volume of distributionNot Available
Protein binding95%
Metabolism

Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine.

SubstrateEnzymesProduct
Orphenadrine
Not Available
N-demethyl orphenadrineDetails
Orphenadrine
Not Available
N,N-didemethyl orphenadrineDetails
Route of eliminationNot Available
Half life13-20 hours
ClearanceNot Available
ToxicityOral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
1,10-PhenanthrolineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Orphenadrine.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational
AmbenoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Orphenadrine.Approved
AprepitantThe serum concentration of Orphenadrine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
AtazanavirThe metabolism of Orphenadrine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Orphenadrine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Orphenadrine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Orphenadrine.Approved, Vet Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Orphenadrine.Approved
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Orphenadrine.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BexaroteneThe serum concentration of Orphenadrine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Orphenadrine.Approved
BoceprevirThe metabolism of Orphenadrine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Orphenadrine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Orphenadrine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Vet Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Illicit, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CeritinibThe serum concentration of Orphenadrine can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Orphenadrine.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CimetropiumOrphenadrine may increase the anticholinergic activities of Cimetropium.Experimental
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Orphenadrine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ClotrimazoleThe metabolism of Orphenadrine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CobicistatThe metabolism of Orphenadrine can be decreased when combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
ConivaptanThe serum concentration of Orphenadrine can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Orphenadrine can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Orphenadrine.Approved
CyclosporineThe metabolism of Orphenadrine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DabrafenibThe serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine.Approved, Investigational
DarunavirThe metabolism of Orphenadrine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Orphenadrine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Orphenadrine can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Demecarium.Approved
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
DexamethasoneThe serum concentration of Orphenadrine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexetimide.Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Vet Approved
DichlorvosThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Orphenadrine.Approved
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
DihydroergotamineThe metabolism of Orphenadrine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
DiltiazemThe metabolism of Orphenadrine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
DonepezilThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Donepezil.Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
DoxycyclineThe metabolism of Orphenadrine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
DronedaroneThe metabolism of Orphenadrine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental
EchothiophateThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Echothiophate.Approved
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
EdrophoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Edrophonium.Approved
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
EluxadolineOrphenadrine may increase the constipating activities of Eluxadoline.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
EnzalutamideThe serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Orphenadrine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Orphenadrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Orphenadrine.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etoperidone.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Illicit, Vet Approved
EtravirineThe serum concentration of Orphenadrine can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FluconazoleThe metabolism of Orphenadrine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
FosamprenavirThe metabolism of Orphenadrine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Orphenadrine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
Fusidic AcidThe serum concentration of Orphenadrine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
GalantamineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Orphenadrine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
Ginkgo bilobaThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.Approved
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
GlycopyrroniumOrphenadrine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Orphenadrine.Approved, Vet Approved
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Orphenadrine.Approved
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Orphenadrine.Approved
IdelalisibThe serum concentration of Orphenadrine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ImatinibThe metabolism of Orphenadrine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Orphenadrine.Approved
IndinavirThe metabolism of Orphenadrine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.Approved
IsavuconazoniumThe metabolism of Orphenadrine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Orphenadrine can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Orphenadrine.Investigational
ItraconazoleThe metabolism of Orphenadrine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Orphenadrine can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
KetoconazoleThe metabolism of Orphenadrine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Illicit
LopinavirThe metabolism of Orphenadrine can be decreased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
LovastatinThe metabolism of Orphenadrine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
LuliconazoleThe serum concentration of Orphenadrine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Orphenadrine can be increased when combined with Lumacaftor.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
MalathionThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
MefloquineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Mefloquine.Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MemantineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Memantine.Approved, Investigational
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Orphenadrine.Approved
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Orphenadrine.Approved
MetyrosineOrphenadrine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Orphenadrine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
MifepristoneThe serum concentration of Orphenadrine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Milnacipran.Approved
MinaprineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MitotaneThe serum concentration of Orphenadrine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Orphenadrine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
NafcillinThe serum concentration of Orphenadrine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
NefazodoneThe metabolism of Orphenadrine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Orphenadrine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Orphenadrine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Orphenadrine can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Orphenadrine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
NVA237The risk or severity of adverse effects can be increased when Orphenadrine is combined with NVA237.Investigational
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
OlaparibThe metabolism of Orphenadrine can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
OsimertinibThe serum concentration of Orphenadrine can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Orphenadrine.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Orphenadrine.Approved
PalbociclibThe serum concentration of Orphenadrine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pancuronium.Approved
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.Approved, Investigational
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Orphenadrine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Physostigmine.Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Orphenadrine.Approved
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Orphenadrine.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PosaconazoleThe metabolism of Orphenadrine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideOrphenadrine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleOrphenadrine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Orphenadrine.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Orphenadrine.Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Orphenadrine.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Propiverine.Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
PyridostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Pyridostigmine.Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Orphenadrine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Orphenadrine.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
RamosetronOrphenadrine may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Orphenadrine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
RifabutinThe metabolism of Orphenadrine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Orphenadrine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Orphenadrine can be increased when combined with Rifapentine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
RitonavirThe metabolism of Orphenadrine can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
RopiniroleOrphenadrine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
RotigotineOrphenadrine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Orphenadrine.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
SaquinavirThe metabolism of Orphenadrine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.Approved, Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
SildenafilThe metabolism of Orphenadrine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Orphenadrine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Orphenadrine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Solifenacin.Approved
St. John's WortThe serum concentration of Orphenadrine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
SulfisoxazoleThe metabolism of Orphenadrine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TacrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Tacrine.Withdrawn
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TelaprevirThe metabolism of Orphenadrine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Orphenadrine can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
TiclopidineThe metabolism of Orphenadrine can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
TiotropiumOrphenadrine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TocilizumabThe serum concentration of Orphenadrine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Orphenadrine.Approved, Investigational
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TrichlorfonThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Orphenadrine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Orphenadrine.Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Orphenadrine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Orphenadrine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tubocurarine.Approved
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Investigational
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Orphenadrine.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Orphenadrine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Orphenadrine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
VoriconazoleThe metabolism of Orphenadrine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Vet Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis ReferenceNot Available
General References
  1. Ji D, Sui ZY, Ma YY, Luo F, Cui CL, Han JS: NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res. 2004 Nov;29(11):2113-20. [PubMed:15662845 ]
External Links
ATC CodesM03BC51N04AB02M03BC01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (247 KB)
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9881
Blood Brain Barrier+0.9134
Caco-2 permeable+0.8654
P-glycoprotein substrateSubstrate0.6196
P-glycoprotein inhibitor IInhibitor0.5825
P-glycoprotein inhibitor IINon-inhibitor0.6378
Renal organic cation transporterInhibitor0.7359
CYP450 2C9 substrateNon-substrate0.7658
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6958
CYP450 1A2 substrateNon-inhibitor0.6363
CYP450 2C9 inhibitorNon-inhibitor0.9191
CYP450 2D6 inhibitorInhibitor0.8949
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9363
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5979
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6341
BiodegradationNot ready biodegradable0.9422
Rat acute toxicity2.8405 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5224
hERG inhibition (predictor II)Inhibitor0.7052
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral50 mg
LiquidIntramuscular; Intravenous30 mg
TabletOral
TabletOral100 mg
InjectionIntramuscular; Intravenous30 mg/mL
Injection, solutionIntramuscular; Intravenous30 mg/mL
TabletOral100 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, multilayerOral
Tablet, extended releaseOral100 mg
Prices
Unit descriptionCostUnit
Norflex 30 mg/ml ampul14.31USD ml
Orphenadrine 30 mg/ml ampule11.25USD ml
Orphenadrine Compound-DS 50-770-60 mg tablet2.94USD tablet
Orphenadrine comp forte tablet2.84USD tablet
Norflex er 100 mg tablet2.67USD tablet
Norflex 100 mg tablet sa2.64USD tablet
Orphenadrine Citrate CR 100 mg 12 Hour tablet2.26USD tablet
Orphenadrine er 100 mg tablet2.17USD tablet
Orphenadrine citrate powder1.6USD g
Orphenadrine comp tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point195 °C at 1.20E+01 mm HgPhysProp
water solubilitySparingly soluble in waterNot Available
logP3.77SANGSTER (1993)
pKa8.91SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.03 mg/mLALOGPS
logP3.5ALOGPS
logP4.17ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity84.97 m3·mol-1ChemAxon
Polarizability31.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9200000000-213fd17f1f5014e79c8bView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Benzylether
  • Toluene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2D
Uniprot ID:
O15399
Molecular Weight:
143750.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN3B
Uniprot ID:
O60391
Molecular Weight:
112990.98 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Rumore MM, Schlichting DA: Analgesic effects of antihistaminics. Life Sci. 1985 Feb 4;36(5):403-16. [PubMed:2578597 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Pubill D, Canudas AM, Pallas M, Sureda FX, Escubedo E, Camins A, Camarasa J: Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999 Mar;51(3):307-12. [PubMed:10344632 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Pubill D, Canudas AM, Pallas M, Sureda FX, Escubedo E, Camins A, Camarasa J: Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999 Mar;51(3):307-12. [PubMed:10344632 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Peng FC, Lin Wu SW: Metabolism of territrem a in liver microsomes from male wistar rats: 3. Cytochrome p-450 isoforms catalyzing tra metabolism. J Toxicol Environ Health A. 2002 Dec 27;65(24):2163-75. [PubMed:12515593 ]
  2. Lin Wu SW, Jean WC, Peng FC, Edwards RJ: Cytochrome P-4503A1 catalyzes the formation of MA1 from territrem a in liver microsomes of 7-week-old female Wistar rats. J Toxicol Environ Health A. 2003 Mar 14;66(5):453-67. [PubMed:12712632 ]
  3. Chang TK, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993 Dec 1;53(23):5629-37. [PubMed:8242617 ]
  4. Stresser DM, Dehal SS, Kupfer D: Ring hydroxylation of [o-3H]methoxychlor as a probe for liver microsomal CYP2B activity: potential for in vivo CYP2B assay. Anal Biochem. 1996 Jan 1;233(1):100-7. [PubMed:8789153 ]
  5. Murray M, Fiala-Beer E, Sutton D: Upregulation of cytochromes P450 2B in rat liver by orphenadrine. Br J Pharmacol. 2003 Jun;139(4):787-96. [PubMed:12813002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Roos PH, Mahnke A: Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem Pharmacol. 1996 Jul 12;52(1):73-84. [PubMed:8678911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M: Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica. 2000 Apr;30(4):327-43. [PubMed:10821163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46